LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).
Conference Call Details:
To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.
Webcast Registration link: https://edge.media-server.com/mmc/p/mdyeh2j3
For further information, please contact:
| Renalytix plc |
www.renalytix.com
|
| James McCullough, CEO |
Via Walbrook PR |
|
|
| Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
| Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea |
|
|
|
| Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
| Gary Clarence / Shalin Bhamra |
|
|
|
| Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com
|
| Paul McManus / Alice Woodings |
Mob: 07980 541 893 / 07407 804 654 |
|
|
| CapComm Partners |
|
Peter DeNardo
|
Tel: 415-389-6400 or investors@renalytix.com
|
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
